The Australia Biomarkers Market was valued at $776.1 Million in 2026 and projected to reach to $1279.8 Million by 2031, representing a compound annual growth rate of 10.5%. Australia's biomarkers market is poised for significant expansion driven by advancing healthcare infrastructure and increasing healthcare expenditure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Australia's biomarkers market is valued at USD 776.1 million in 2026 and is projected to reach USD 1,279.8 million by 2031, representing a robust 10.5% CAGR over the forecast period.
Increasing adoption of precision medicine across Australian healthcare institutions is driving demand for advanced biomarker diagnostics, enabling personalized treatment approaches and improved patient outcomes.
Australia's well-established regulatory environment and TGA oversight provide a stable foundation for biomarker innovation, attracting both domestic and international diagnostic companies to invest in the market.
Australia's leading research institutions and universities are advancing biomarker discovery and validation, positioning the country as a hub for diagnostic innovation and clinical applications.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
NGS-based comprehensive genomic profiling (CGP) and multi-omic biomarkers (including high-sensitive Troponin T, NT-proBNP) for cancer, cardiovascular, and neurology applications. | Supports personalized treatment plans, rapid rule-in/rule-out diagnostics from single tests, earlier detection, and companion diagnostics across oncology, cardiology, and neurology. |
|
|
High-sensitivity immunoassays and blood-based biomarkers for cancer, cardiovascular, and neurological diseases, including amyloid β testing for Alzheimer’s. | Enables non-invasive early diagnosis, risk stratification, and monitoring for chronic conditions like Alzheimer's, cancer, and CVD. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SAFETY BIOMARKERS (Type) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 10.5% from 2026 to 2031 |
| Largest Segment | CONSUMABLES (Offering) |
| Market Size Base Year (Billions) | ~USD 68.04 (2026) |
| Revenue Forecast (Billions) | ~USD 112.1 (2031) |
| Segments Covered | Offering, Type, Research Area, Technology, Application, Disease Indication, End User |
7 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 153.5 | 175.5 | 187 | 202.9 | 221.8 | 243.7 | 268.4 | 296 | 9.6 |
| HOSPITALS & DIAGNOSTIC LABORATORIES | 192.8 | 221.1 | 236.2 | 257.2 | 282 | 310.8 | 343.4 | 379.9 | 10 |
| OTHER END USERS | 110.2 | 125.5 | 133 | 143.6 | 156.1 | 170.7 | 187 | 205.1 | 9.1 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 330.5 | 381.8 | 411.5 | 452 | 500 | 556 | 619.7 | 691.6 | 10.9 |
| TOTAL | 787 | 903.9 | 967.7 | 1055.7 | 1159.8 | 1281.2 | 1418.4 | 1572.6 | 10.2 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BECKMAN COULTER | United States | Private Company | Clinical diagnostics systems (chemistry, hematology, immunoassay, urinalysis, blood bank),Laboratory automation and information systems,Life science research instruments and genomic solutions, |
| PRA HEALTH SCIENCES | United States | Private Company | Clinical Research (Phase I-IV services across key therapeutic areas),Data Solutions (analytics, data platforms, and related services), |
| ROSETTA GENOMICS | Israel | Public Company | RosettaGX Cancer Origin and microRNA cancer-of-origin tests,RosettaGX Reveal (indeterminate thyroid FNA),mi-LUNG and mi-KIDNEY microRNA assays, |
| TRANSGENOMIC, INC. | United States | Public Company | Oncology and pharmacogenomics lab services,Multiplexed ICE COLD-PCR reagents,Other genomic testing technologies and platforms, |
| CELGENE CORPORATION | United States | Private Company | REVLIMID (lenalidomide),POMALYST/THALOMID (IMiD franchise ex-REVLIMID),ABRAXANE and VIDAZA/ONUREG/ISTODAX (solid tumor and myeloid oncology), |
| PFIZER | India | Public Company | Internal medicine (cardiovascular, metabolic, respiratory, gastroenterology),Vaccines,Injectables and anti-infectives (including hospital services), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology,Life Sciences,Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing consumables (reagents, flow cells, library prep),Sequencing instruments,Arrays and genotyping solutions, |
| MERCK KGAA | Germany | Public Company | Life Science (lab reagents, consumables, instruments, bioprocessing, CDMO/testing services),Healthcare (oncology, rare diseases, neurology/immunology, fertility, cardiovascular, metabolic/endocrine),Electronics (semiconductor materials, specialty gases, delivery equipment, display and photonics materials), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions (reagents, instruments, consumables),Analytical Instruments,Specialty Diagnostics, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables & instruments,Molecular diagnostics assays (TB, oncology, SRH, transplant, viral load),PCR & digital PCR reagents and instruments, |
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| REVVITY INC. | United States | Public Company | Diagnostics instruments, assays, and software (prenatal, neonatal, infectious disease),Life science reagents, antibodies, and assay platforms,Detection and imaging instruments and related consumables, |
| CHARLES RIVER LABORATORIES | United States | Public Company | Discovery and Safety Assessment,Research Models and Services,Manufacturing Solutions, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Instruments and Systems,Life Science Reagents and Consumables, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food & Feed Testing,Environment Testing,Biopharma & Clinical Diagnostics, |
| BIOMéRIEUX | France | Public Company | Clinical microbiology (culture media, ID/AST, blood culture, sepsis markers),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Industrial applications (food, pharma, environmental: GENE-UP, VERIFLOW, BIOBALL, TEMPO, ENDONEXT, CHEMUNEX), |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, display and CMP materials),Plastics and Synthetic Resins (ABS, AES, AS, ASA),Life Sciences (diagnostic reagents, bioprocess materials, drug discovery support), |
| GUARDANT HEALTH | United States | Public Company | Guardant360 (CDx and Liquid),Other oncology tests (Reveal, Tissue, OMNI, INFINITY),Shield colorectal cancer screening, |
Beckman Coulter is a private company founded in 1935 in the United States with 11,900 employees. The company operates in the diagnostics and life sciences sector.
PRA Health Sciences is a private United States-based company founded in 1976 with 18,100 employees. The company provides clinical research and development services.
Rosetta Genomics is a public Israeli company founded in 2000 with 86 employees. The company focuses on genomic and molecular diagnostics.
Transgenomic, Inc. is a public United States company founded in 1997 with 19 employees. The company operates in the genetic analysis and diagnostics sector.
Celgene Corporation is a private United States company founded in 1986 with 8,852 employees. The company specializes in biopharmaceutical research and development.
Pfizer is a public company founded in 1950 in India with 1,244 employees. The company operates in the pharmaceutical sector.
Danaher Corporation is a public United States company founded in 1969 with 59,000 employees. The company operates across diversified segments including diagnostics and life sciences.
Illumina, Inc. is a public United States company founded in 1998 with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
Merck KGaA is a public German company founded in 1668 with 62,136 employees. The company operates in pharmaceuticals, life sciences, and performance materials.
Thermo Fisher Scientific Inc. is a public United States company founded in 1956 with 125,000 employees. The company is a global leader in life sciences, analytical instruments, and laboratory services.
Qiagen is a public Dutch company founded in 1984 with 5,500 employees. The company specializes in molecular diagnostics and sample preparation technologies.
Abbott is a public United States company founded in 1888 with 115,000 employees. The company operates across diagnostics, medical devices, pharmaceuticals, and nutrition.
Agilent Technologies, Inc. is a public United States company founded in 1999 with 18,000 employees. The company provides analytical instruments and life sciences solutions.
Revvity Inc. is a public United States company founded in 1937 with 11,000 employees. The company operates in diagnostics, life sciences, and analytical instruments.
Charles River Laboratories is a public United States company founded in 1947 with 19,000 employees. The company provides preclinical and clinical laboratory services for drug development.
Bio-Rad Laboratories, Inc. is a public United States company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.
Eurofins Scientific is a public Luxembourg company founded in 1987 with 65,694 employees. The company provides laboratory testing and analytical services across multiple industries.
bioMérieux is a public French company founded in 1963 with 14,894 employees. The company specializes in in vitro diagnostics and microbiology testing solutions.
JSR Corporation is a private Japanese company founded in 1948 with 7,997 employees. The company operates in materials science and life sciences sectors.
Guardant Health is a public United States company founded in 2011 with 2,498 employees. The company specializes in liquid biopsy and genomic testing for cancer detection and monitoring.
Australia's biomarkers market is valued at USD 776.1 million in 2026 and is expected to reach USD 1,279.8 million by 2031.
Australia's biomarkers market is projected to grow at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2031.
Key drivers include Australia's aging population, rising prevalence of chronic diseases, increased adoption of precision medicine, and government healthcare initiatives supporting diagnostic innovation.
Australia's biomarkers market is dominated by oncology, cardiovascular, and infectious disease diagnostics, with growing adoption of liquid biopsy and molecular diagnostic technologies.
Australia represents a significant portion of the Asia Pacific biomarkers market, driven by advanced healthcare infrastructure, strong regulatory frameworks, and substantial research and development capabilities.
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives at major market players, and industry consultants, to gather and validate critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the global biomarkers market. The secondary sources used for this study include the American Society of Clinical Oncology (ASCO), Association for Molecular Pathology (AMP), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organisation (CDSCO), Center for Disease Evaluation and Research (CDER), Clinical Laboratory Standards Institute (CLSI), Centers for Disease Control and Prevention (CDC), Clinicaltrials.gov, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), Ministry of Food and Drug Safety (MFDS), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), National Medical Products Administration (NMPA), Organisation for Economic Co-operation and Development (OECD), Personalized Medicine Coalition (PMC), Population Health Research Institute (PHRI), Pharmaceuticals and Medical Devices Agency (PMDA), World Bank, World Health Organization (WHO), corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations, among others. These sources were also used to obtain key information on major players, market classification and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.
Following an initial assessment of the global biomarkers market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were conducted with key supply-side participants, including C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% were conducted with demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephone discussions to comprehensively understand market dynamics.
The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
Both bottom-up and top-down approaches were used to estimate and validate the total size of the global biomarkers market. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
A biomarker is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response. Biomarkers can be molecular, histologic, radiographic, or physiological characteristics that provide valuable insights into normal and pathological processes.
The biomarkers market encompasses a broad range of products and services that support biomarker discovery, validation, and application in clinical and research settings. This includes offerings such as consumables (assay kits, reagents, and instruments), software tools, and related services that facilitate biomarker analysis. The market report analyzes biomarker usage across multiple applications, including clinical diagnostics, drug discovery & development, personalized medicine, and clinical research. It also examines the adoption of biomarkers across key research areas, including oncology, neurology, cardiology, infectious diseases, and metabolic disorders. Furthermore, the report segments the market by type into safety, efficacy, and validation biomarkers. The study also considers regional trends, end-user adoption, and technological advancements shaping the global biomarkers landscape.
With the given market data, MarketsandMarkets offers customizations to meet the company’s needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Biomarkers Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report